Home / Health / Foundayo: UK's First Oral GLP-1 for Diabetes & Weight Loss
Foundayo: UK's First Oral GLP-1 for Diabetes & Weight Loss
11 Aug
Summary
- Foundayo, a new daily weight loss pill, is now approved in the UK.
- It mimics natural hormones to reduce appetite and blood sugar levels.
- The pill will be available privately, not on the NHS, launching this month.
The UK has approved Foundayo, a new daily oral medication for weight loss and type 2 diabetes. Developed by Eli Lilly, the pharmaceutical company behind Mounjaro, Foundayo is a GLP-1 receptor agonist. This class of drugs works by imitating the body's natural hormones that regulate blood sugar and appetite.
Foundayo offers a convenient once-daily dosage and can be taken without specific food or water restrictions, differentiating it from other available oral GLP-1 medications. While clinical benefits for weight loss are significant, they may be less pronounced than some other treatments. The drug will be launched this month via private prescription, with its UK list price expected to be lower than Mounjaro.
Despite its approval, Foundayo will not be accessible through the NHS at this time. Common side effects may include nausea, diarrhoea, and stomach cramps, with less frequent possibilities such as fatigue and vision problems. Patients should consult healthcare professionals regarding potential risks and benefits.
